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ABSTRACT
Background and Aims Naloxone is an opioid antagonist used for emergency resuscitation following opioid overdose.
Prisoners with a history of heroin injection have a high risk of drug-related death soon after release from prison. The NAL-
oxone InVEstigation (N-ALIVE) pilot trial (ISRCTN34044390) tested feasibility measures for randomized provision of
naloxone-on-release (NOR) to eligible prisoners in England. Design. Parallel-group randomized controlled pilot trial.
Setting English prisons. Participants A total of 1685 adult heroin injectors, incarcerated for at least 7 days
pre-randomization, release due within 3 months and more than 6 months since previous N-ALIVE release.
Intervention Using 1 : 1 minimization, prisoners were randomized to receive on release a pack containing either a single
‘rescue’ injection of naloxone or a control pack with no syringe. Measurements Key feasibility outcomes were tested
against prior expectations: on participation (14 English prisons; 2800 prisoners), consent (75% for randomization),
returned prisoner self-questionnaires (RPSQs: 207), NOR-carriage (75% in ﬁrst 4 weeks) and overdose presence (80%).
Findings Prisons (16) and prisoners (1685) were willing to participate [consent rate, 95% conﬁdence interval
(CI) = 70–74%]; 218 RPSQswere received; NOR-carriage (95%CI = 63–79%) and overdose presence (95%CI = 75–84%)
were as expected. We randomized 842 to NOR and 843 to control during 30 months but stopped early, because only
one-third of NOR administrations were to the ex-prisoner. Nine deaths within 12 weeks of release were registered for
1557 randomized participants released before 9 December 2014. Conclusions Large randomized trials are feasible with
prison populations. Provision of take-home emergency naloxone prior to prison release may be a life-saving interim
measure to prevent heroin overdose deaths among ex-prisoners and the wider population.
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INTRODUCTION
Prisoners with a history of heroin injection have a high risk
of drug-related death (DRD) soon after prison release,
which was estimated at ﬁve DRDs per 1000 eligible
releases on the basis of record-linkage studies in Scotland
in 1996–99 [1] and in England and Wales in
1999–2002 [2]; also see meta-analyses [3,4].
Naloxone is an opioid antagonist that can be adminis-
tered intramuscularly and is used by emergency services
to reverse heroin/opioid overdose [5]. The feasibility of
randomized provision of naloxone-on-release (NOR) to a
high-DRD risk population, such as inmates with a history
of heroin injection use on their release from prison, as
proposed by Bird & Hutchinson [1], had not been investi-
gated. Prison-based randomized trials must address either
a concern that applies speciﬁcally to prisoners (as here) to
counter the challenge that the same trial could have been
conducted equally well in the outside community or be able
to point to parallel trials on the outside to answer the
challenge of exploiting prisoners’ captivity.
One recent international review of non-randomized
community initiatives on take-home naloxone, mainly in
the United States and the United Kingdom, with
follow-up for 3–6 months of their trainees, gave an
estimated fatality rate at witnessed opioid overdose of 6%
(upper 95% conﬁdence limit = 11%), suggesting that a
target for the annual distribution of naloxone kits should
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be nine to 20 times a nation’s annual number of opioid-
related deaths [6]. A recent comprehensive monograph [7]
has documented the historical development (from the
1990s) and spread of take-home naloxone programmes
through North America, Europe and Australia and
considered their practical implementation, including the
training of naloxone recipients in how to recognize and
respond to an overdose. Although supported by the World
Health Organization (WHO) [8], barriers remain to
accessing take-home naloxone: in most European
jurisdictions, naloxone is a prescription-only medicine; in
others (see below), its addition to the exempt list of
prescription-only medicines did little to change clinical
practice, take-home naloxone being deemed contentious
[9] by some, complex [10] by others. When the
notiﬁcation of overdose events triggers a report to the
police, this may discourage witnesses from contacting
emergency medical services, and the need to inject nalox-
one can prove a psychological barrier for some responders
as well as being a potential health risk for all who adminis-
ter the injection [7].
In 2005, naloxone was added to the UK’s exempt list of
prescription-only medicines that can be administered by
anyone to save life in an emergency [11,12]. Bird et al.
then applied to the UK Medical Research Council (MRC)
for funding to conduct a randomized effectiveness study
of NOR for prisoners with a history of heroin use by injec-
tion. The deﬁnitive NALoxone InVEstigation (N-ALIVE)
trial was to investigate if NOR could reduce DRDs in the
ﬁrst 4 weeks after release by 30% and in weeks 5–12 by
20%. In 2008, the Medical Research Council (MRC)
funded the N-ALIVE pilot trial to randomize the ﬁrst tenth
of 56000 prisoners needed for the main trial: half in
Scotland, the other half in 15 prisons in England and
Wales. The rationale for the N-ALIVE trial has been
described previously [9].
In January 2011, Scotland became the ﬁrst nation to
make both community-based take-home naloxone and
NOR for eligible prisoners a public health-funded policy
[6,13–15]. Wales followed suit later in 2011 [16]. Ac-
cordingly, N-ALIVE was conducted in English prisons
only, and its target accrual reduced to 2800
participants.
Our a priori estimation of the probable effectiveness of
naloxone [1] accounted for someone else being present at
four-ﬁfths of opiate overdoses [12]; and that, most often,
the others present (peers or family-members) were willing
to intervene but lacked effective means [17].
We report the key feasibility outcomes of the N-ALIVE
pilot trial, compared with prior expectations in the trial
protocol (ISRCTN34044390) [18], as follows:
(i) participation by prisons and prisoners;
(ii) consents for randomization, returned prisoner self-
questionnaire (RPSQ), telephone-contact substudy;
(iii) receipt of RPSQs;
(iv) NOR carriage and overdose presence; and
(v) whether the N-ALIVE main trial could go ahead as
planned, including assessment of to whom NOR was
administered.
METHODS
Design: plausible effectiveness and main trial size, plus key
assumptions to be checked by pilot trial
N-ALIVE was a randomized controlled trial of parallel
groups (see Fig. 1). Research-trained prison-based
N-ALIVE workers recruited and consented eligible
prisoners.
The N-ALIVEmain trial was to investigate if NOR could
reduce DRDs in the ﬁrst 4 weeks after release by 30%, from
140 to 98 per 28000 eligible releases; and in weeks 5–12
by 20%, from 35 to 28 per 28000 eligible releases, for
which randomization of 56000 eligible releases would be
needed for 80% power at a 5% signiﬁcance level. In 2008,
MRC funded the N-ALIVE pilot trial to randomize the ﬁrst
tenth of 56000 prisoners needed for the main trial: half
in Scotland, the other half in prisons in England andWales.
Our a priori estimation of NOR’s probable effectiveness
in the main trial took into account that: (a) someone else
is present at 80% of opiate overdoses [12]; (b) 75% of
ex-prisoners randomized to NOR would carry NOR in the
ﬁrst 4 weeks, reducing to 50% in weeks 5–12, but
negligible thereafter [18]; (c) most often, the others present
(peers or family members) arewilling to intervene [17] but,
conservatively, we assumed a 50 : 50 chance that others
present would have the presence of mind to locate,
assemble and administer NOR to the ex-prisoner [18].
Hence, NOR’s plausible effectiveness at reducing DRDs
was 80 × 75 × 50%, or 30%, in the ﬁrst 4 weeks, but
reduced to 20% in weeks 5–12.
In Scotland and in England and Wales, the N-ALIVE
pilot trial was to test our key assumptions on (i) participa-
tion, (ii) consents, (iii) receipt of RPSQs, (iv) NOR carriage
and overdose presence, and hence (v) whether the
N-ALIVE main trial could go ahead as planned, including
by assessment of to whom NORwas administered.
Because the N-ALIVE pilot trial could randomize in
English prisons only, its target accrual reduced to 2800
participants, sufﬁcient for assessing (i)–(v) for England.
Key outcome measures and prior expectations for the
pilot trial [18] are detailed in Table 1. The N-ALIVE
pilot trial was approved by Essex 2 Research Ethics
Committee.
Data collection
Study forms were sent by our prison-based N-ALIVE
workers to MRC Clinical Trials Unit by post or fax.
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Reporting of release date was particularly important as
marking the start of a participant’s at-risk period.
Screening logs for eligibility were introduced in Septem-
ber 2012.
The randomization form checked a potential partic-
ipant’s eligibility and consents and provided the infor-
mation needed for minimization (see below). Other
forms recorded the participant’s release date or date
of prison transfer. Information on date and cause of
death within 4 weeks, 12 weeks and 6 months of a
participant’s N-ALIVE release date was obtained from
the Ofﬁce for National Statistics by checking periodi-
cally against registered deaths, most recently on 21
April 2016. The RPSQ was designed to answer objec-
tives (iv) and (v).
Eligibility, randomization and consent
Eligibility criteria were age greater than 18 years (upper
limit of 44 removed 16 months into the trial because
10% of otherwise eligible prisoners were being excluded,
see Table 2), history of heroin use by injection,
incarcerated for at least 7 days, expected release date
within 3 months of randomization date, not previously
randomized in N-ALIVE trial and then consent
withdrawn prior to release, and written informed con-
sent. Exclusion criteria were known history of anaphy-
lactic reaction to naloxone, conﬁrmed/declared
pregnancy or pregnancy intended within 6 months, nor-
mally resident outside the United Kingdom, and random-
ization date within 6 months of most recent N-ALIVE
release-date (or, if missing, within 1 year of previous
randomization date).
Participants were randomized (1:1) by the MRC
Clinical Trials Unit to receive on release a pack contain-
ing either a single ‘rescue’ injection of naloxone or a
control pack which did not contain naloxone—there
was no placebo. Minimization (with 80 : 20 randomiza-
tion) was applied across gender, age group (18–24,
25–34, 35+ years), re-randomization, management of
opioid dependency at randomization (substitution,
detoxiﬁcation, other) and probable interval from
randomization to index release (within 28 days,
4–12 weeks).
Figure 1 NALoxone InVEstigation (N-ALIVE) pilot trial design and outcomemeasures. A full list of the trial’s outcomemeasures is described in the
N-ALIVE protocol, which is available on the N-ALIVE webpage: http://www.ctu.mrc.ac.uk/13391/13399/18277/n-alive_trial_protocol
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Table 1 Feasibility outcomes: summary of prior assumptions and actual ﬁndings.
Outcome Prior assumption Actual Comment
Number of participating
prisons
11 prisons in Scotland
14 prisons in England
16 prisons in England (15 open,
1 closed to recruitment)
Consistent with expectation
Target participant accrual 5600 participants
Original sample size
requirement was up
to 10% of 56000
participants
Target revised down to 2800 for
England due to non-participation
of prisons in Scotland
and Wales
February 2014: interim target
revised to 1500 by 31
August 2014
Actual accrual at 31 August
2014 was 1392 participants
1500 participants achieved
on 8 October 2014
Final accrual at 8 December
2014: 1685 participants
Early cessation, see Fig. 3
Consent for randomization
by eligible prisoners
75% Based on screening logs, the
consent-rate for randomization
among eligible prisoners
was 72% (1283 of 1777);
95% CI = 70–74%
Upper 95% conﬁdence limit
is just short of our prior
expectation
Consent to returned prisoner
self-questionnaire (RPSQ)
Prior expectation of 75% Consent to complete the RPSQ
was given by 85% of participants
(1417 of 1676); 95% CI = 83–86%
Above expectation
Consent to secondary
randomization in the
telephone-contact
ancillary study
Prior assumption of 50% Consent to take part in the
telephone contact study was
provided by 56% (946 of 1676);
95% CI = 54–59%
Above expectation
Number of RPSQs 333 recidivist
self-questionnaires
expected from 2500
randomized and released
participants, so we expected
333 of 2500 × 1557 = 207
RPSQs
218 received from 1557
randomized and released
participants
Consistent with expectation
Carriage rate in ﬁrst
4 weeks after release
75% RPSQ 71% (80 of 112)
95% CI = 63–79%
Consistent with expectation
Someone else present
at overdose
80% Based on RPSQs: 53 of 205
recidivists (26%; 95% CI = 20–32%)
of recidivists reported having
injected when alone, and had
done so on a mean of 6 of
14 days. Hence, 95% CI for
someone else present is 68–80%
Telephone questionnaire: heroin
use in the past 3 days was
reported by 31 of 81 telephone
contacts (38%), 10 of whom
had injected when alone
(12%; 95% CI = 5–20%). If
the past 3-day rate is taken
as representative of the rate
throughout the ﬁrst 4 weeks,
then 95% CI for someone else
being present at injector’s overdose
is 80–95%
Consistent with expectation
(Continues)
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Consent for mortality follow-up was mandatory at the
time of consent for randomization, but could bewithdrawn
while participants were still in prison: in such a case, the
participant would be withdrawn from the trial and no
attempt would be made to provide a pack on release.
Additionally, prisoners were asked for their consent for (i)
record-linkage to establish if participants had had any
admissions to accident and emergency departments for
non-fatal overdose in the 12 weeks following their
N-ALIVE release-date; and (ii) randomization in a
once-only telephone contact substudy [18],; see Fig. 1
and Supporting Information.
The trial was double-blind prior to release so that,
while the participant was still in custody and pre-release,
neither the participant, prison-based N-ALIVE staff nor
prison staff knew the allocation. Participants learned
their allocation when they opened the pack at the time
of their release.
N-ALIVE packs
Each prison had a supply of pre-numbered sealed
N-ALIVE packs (Meade et al., in review). Control and
naloxone packs were identical in appearance, sounded
alike when shaken and were similar weights. All packs
contained the N-ALIVE DVD, a wallet and had tamper-
evident stickers attached.
Thewallet in the control pack did not contain a syringe.
The wallet in the naloxone pack included all the same
material as the control wallet, but also contained a pre-
ﬁlled syringe, the unscrewed plunger rod for the syringe
and a safety-covered, sterile-packed hypodermic needle;
Table 1. (Continued)
Outcome Prior assumption Actual Comment
Both consistent with our prior
expectation that someone else
is present at 80% of opiate
overdoses
Pooled estimate (based on
weights 61% and 39%) is
79%; 95% CI = 75–84%
Telephone questionnaire
phone contacts in the
ﬁrst or second fortnight
Based on the (probability
of consent) × (probability
of being randomized to
telephone contact given
consent) × (probability of
contact given randomized
to telephone contact) =
1/8 × number randomized
and released (1557) = 195
81 of 1557 randomized and
released participants
Poisson 95% CI = 63–99
Well below expectation
Drug-related deaths in
ﬁrst 4 weeks and next
8 weeks after release
We expect 1/200 × 1557 =
7.9 or 8 DRDs in ﬁrst 4 weeks
after release if NOR is not
effective; and a further
1/800 × 1557 = 1.9 or
2 DRDs in the next 8 weeks
2 DRDs in ﬁrst 4 weeks
post-release; a further 3 DRDs in
the next 8 weeks were registered
with Ofﬁce for National Statistics
by 21 April 2016 First 4 weeks,
95% CI = 0.2–7.2
12 weeks, 95% CI = 1.6–11.7
Below expectation for the
ﬁrst 4 weeks; consistent
with expectation in the
ﬁrst 12 weeks
Non-fatal overdose-related
admissions within
12 weeks of release
We assume participants’
non-fatal overdose
admissions to Accident and
Emergency within 12 weeks
of index release to be
between two and eight times
as many as DRDs with 2–3
times as many DRDs being
our best estimate, thus we
expect 20–30 (but up to 80)
non-fatal overdose-related
Accident and Emergency
admissions
Awaiting Hospital Episode
Statistics data from Health and
Social Care Information Centre
(now NHS Digital)
No information
CI = conﬁdence interval; DRD = drug-related deaths; NOR = naloxone-on-release.
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see Supporting information. The plunger had been
removed from the syringe barrel so that both ﬁtted into
the N-ALIVE wallet; both had to be ﬁtted to the syringe
before use. The syringe contained 2 mg of naloxone
hydrochloride in 2 ml of solution, for once-only
intramuscular injection in the event of overdose. During
information and consent sessions, participants were
advised on how to administer the N-ALIVE-recommended
0.8 mg intramuscular dose of naloxone. For trial purposes,
the naloxone needed to be a single product (see Meade et
al., in review). As none of the available products ﬁtted
our needs well, the correct dose in single product form
was most crucial. Accordingly, we selected the 2-mg
pre-loaded syringe as an acceptable formulation for the
pilot trial period (see Meade et al. in review), which
necessitated additional instructions for administration to
be limited to a 0.8 mg dose.
Returned prisoner self-questionnaire
We asked participants if they were willing to complete an
anonymous follow-up questionnaire if they returned to
prison within 6 months of their most recent N-ALIVE
release date. The RPSQ identiﬁed the participant’s
randomized assignment and the time interval between the
preceding N-ALIVE release date and completion date but,
to encourage frankness, the identity of the respondent was
not recorded. Forms were neither checked nor overseen by
the N-ALIVE worker unless the respondent so chose.
Statistical analysis
All validly randomized participants who were released
from custody before 9 December 2014 are included in
the analyses.
Simple summary statistics for percentages or counts
[together with 95% conﬁdence intervals (CIs)] are used to
assess consistency with prior expectations: on consents,
RPSQs, NOR carriage in the ﬁrst 4 weeks, overdose
presence and the use made of NOR to save the life of others
than those for whom itwas prescribed. Comparison of rates
between NOR versus control group, based on RPSQs, is by
χ2 or Fisher’s exact test, as appropriate.
Formal comparison of risk behaviours versus percep-
tion between NOR versus control is based on a composite
score for risk behaviours, derived post hoc from RPSQs.
Early cessation of randomization in the N-ALIVE pilot trial
made it unlikely that subsequent NOR evaluations would
be randomized individually. We therefore needed to make
best use of the N-ALIVE pilot trial’s data to explore whether
those randomized to NOR had increased the riskiness of
their heroin use soon after release, as distinct from how
participants perceived that their behaviour had been
changed by taking part in N-ALIVE.
Table 2 Baseline characteristics for 1557 participants randomized and released by 8 December, 2014.
Characteristic NOR Control All
Age (Mean SD) years
Mean 35 years
SD 7 years
Mean 35 years
SD 6 years
Mean 35 years
SD 7 years
n % n % n %
Age categories (n, %) years
18–24 40 5 40 5 80 5
25–34 381 50 385 50 766 50
35–44 290 38 302 39 592 39
45+ 47 6 46 6 93 6
Gender (n, %)
Males 762 98 771 98 1533 98
Females 12 2 12 2 24 2
Treatment for addiction (at randomization) (n, %)
Opiate substitution 496 64 503 64 999 64
Opiate detoxiﬁcation 163 21 163 21 326 21
Other (e.g. naltrexone, no current treatment) 114 15 116 15 230 15
Not recorded 1 <1 1 <1 2 <1
Probable incarceration interval (n, %)
(Date of randomization–expected release date at randomization)
Within 28 days 532 69 540 69 1072 69
4–12 weeks 171 22 175 22 346 22
>12 weeks 17 2 13 2 30 2
Unknown release date 54 7 55 7 109 7
SD = standard deviation. NOR = naloxone-on-release
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Risk score
To analyse how provision of NOR impacted on participants’
heroin use and related risk behaviours soon after release, a
risk score based on RPSQ responses was devised by S.M.B.
and A.M.M. and agreed by J.S. and M.K.B.P. (see
Supporting information for how individual questions were
scored), before being implemented by L.C. and tested for
interaction (NOR versus control) against perceived
behaviour change.
RESULTS
Recruitment: prisons and participants
The trial was conducted in 16 prisons in England. Based on
screening logs, the consent rate for randomization among
eligible prisoners was 72% (1283 of 1777, 95%
CI = 70–74%), just short of our prior assumption of 75%
(Table 1).
Between 28 May 2012 and 8 December 2014, we
randomized 1685 participants (842 to NOR; 843 to
control). Nine participants are considered ‘not random-
ized’ because they were withdrawn prior to release:
four withdrew consent for mortality follow-up prior to
their release, while ﬁve were found to be ineligible, see
Fig. 2 [Consolidated Standards Of Reporting Trials
(CONSORT)].
Consent to complete the RPSQ was given by 85% of
participants (1417 of 1676), better than our prior
expectation of 75%. Consent to take part in the telephone
contact study was provided by 56% (946 of 1676, 95%
CI = 54–59%) of participants, better than our prior
assumption of 50%.
Re-randomizations
Of the 129 participants randomized more than once, 61
had received naloxone on the ﬁrst occasion while 68
received control, consistent with expectation (64.5 each)
if prior allocation did not inﬂuence the decision to be
re-randomized.
Early cessation of randomization: decisions by the Trial
Steering-Data Monitoring Committee (TS-DMC)
We closed the trial to accrual on 8 December 2014, ahead
of our planned closure date (Bird et al. in review). An un-
scheduled interim analysis of the feasibility outcomes of
the N-ALIVE pilot trial was prompted by the release on
28October 2014 of the third year of results from Scotland’s
National Naloxone Programme [19]; see Fig. 3.
When randomization to N-ALIVE stopped, all
participants who remained in custody were to be offered
naloxone on their release, including those due to receive
a control pack. The Principal Investigators at our prisons
so agreed. Participants were otherwise followed-up as per
protocol.
Figure 2 Consolidated Standards Of Reporting Trials (CONSORT) Diagram for the NALoxone InVEstigation (N-ALIVE) pilot Trial. Screening
records have been kept only since September 2012 to provide a snapshot of the proportions deemed eligible and subsequently randomized.
*Excluded from intention-to-treat (ITT) analysis participants released after recruitment closure (n = 48, 40). **Included in per-protocol (PP) analysis
participants released with pack only
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Baseline characteristics
The baseline characteristics and treatment allocation of
the 1557 randomized participants who were released by
8 December 2014 (93% of the 1676 who were eligible to
receive a pack on release) are shown in Table 2.
Provision of packs on release
Of those participants released before 8 December 2014,
81% received their N-ALIVE pack on release (1266 of
1557; 95% CI = 79–83%).
RPSQs: return-rate and ﬁndings
We received 218 of 1557 (14%) RPSQs by 8 December
2014, 205 with information on treatment assignment
(112 naloxone; 93 controls), consistent with our prior
expectation of 207 (95% CI = 179–235); see Table 1.
Median and mean time [standard deviation (SD)] from
release date to RPSQ completionwere 64 and 80 (62) days.
(a) Naloxone carriage and administration
Of RPSQ respondents assigned to NOR, 76% (85 of 112;
95% CI = 68–84%) told a family member or friend about
their naloxone (Table 3) and 71% (80 of 112; 95%
CI = 63–79%) reported carriage of naloxone in the ﬁrst 2
weeks post-release, consistent with prior expectation
(Table 1). Naloxone acquisition from other sources
occurred at a non-differential low rate (12 of 205, 95%
CI = 2.6–9.1%). More often, RPSQ respondents reported
that their NOR had been administered to ‘save’ someone
else (14%; 16 of 112) than themselves (5%; ﬁve of 112);
see also Fig. 3.
Twenty-one per cent (23 of 112) reported administra-
tion of naloxone to themselves or another before the arrival
of a doctor or ambulance versus 9% (eight of 93) for
controls (χ2 on 1 d.f. = 5.64; P = 0.02). Cumulative
accounting for overdose victims being taken to hospital
was 26% (29 of 112) for NOR versus 28% (26 of 93) for
controls; χ2 on 1 d.f. = 0.11 (P = 0.74).
(b) Personal drug use, injecting and overdose events
Two-thirds of RPSQ respondents had used heroin in the
ﬁrst fortnight post-release (67%, 137 of 205).
Half (105 of 205) of the RPSQ respondents had injected
in the ﬁrst fortnight—58% (65 of 112) for NOR and 43%
(40 of 93) of controls; 26% (53 of 205; 95% CI = 20–32%)
had injected when alone during the ﬁrst 2 weeks
post-release, on a mean of 6 days out of 14 (95%
CI = 4.9–7.1 days), broadly consistent with our prior
Figure 3 Explanation of the decision by the NALoxone InVEstigation (N-ALIVE) Trial Steering—Data Monitoring Committee (TS-DMC) to cease
randomization in the N-ALIVE pilot trial
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Table 3 Responses to returned prisoner self-questionnaire.
Self-questionnaire NOR Control Total
Number of forms completed 112 (51%) 93 (43%) 205
Time from previous release to
completion of questionnaire (days)
Mean 79, SD 59 Mean 85, SD 66 Mean 82, SD 63
Median 64 Median 64 Median 64
IQR = 37–108 IQR = 39–119 IQR = 38–108
Told family member/friend about naloxone 76% (85/112) NA NA
Told someone about naloxone 79% (89/112) NA NA
Carriage rate of naloxone 71% (80/112) NA NA
How often did you carry it?
All 76% (61/80)
Most 16% (13/80) NA NA
Some 6% (5/80)
No response 1% (1/80)
What did you do with the naloxone? NA NA
Saved other 14% (16/112)
Saved self 5% (5/112)
Lost it 13% (14/112)
Had it taken away/stolen 10% (11/112)
Given it away 7% (8/112)
Thrown it away 2% (2/112)
Broke the syringe 2% (2/112)
No answer given 48% (54/112)
Heroin use in the ﬁrst 2 weeks after leaving prison
(yes or no) 69% (77/112) 65% (60/93) 67% (137/205)
(Smoke/inject) 66% (74/112) 65% (60/93) 65% (134/205)
n = 74 n = 60 n = 134
Mean 9/14 days, Mean 8/14 days, Mean 9/14 days,
SD 5 days SD 5 days SD 5 days
(Inject) 58% (65/112) 43% (40/93) 51% (105/205)
n = 65 n = 40 n = 105
Mean 9/14 days, Mean 10/14 days, Mean 9/14 days,
SD 5 days SD 5 days SD 5 days
(Inject, alone) 23% (26/112) 29% (27/93) 26% (53/205)
n = 25 n = 26 n = 51
Mean 6/14 days, Mean 6/14 days, Mean 6/14 days,
SD 5 days SD 4 days SD 4 days
Self-overdose <2 weeks of release
Overdose* 7% (8/112) 2% (2/93) 5% (10/205)
Someone present 8/8 1/2 9/10
Naloxone given 3/8 2/2 5/10
Taken to hospital 4/8 2/2 6/10
Self-overdose >2 weeks of release
Overdose 4% (5/112) 6% (6/93) 5% (11/205)
Someone present 3/5 6/6 9/11
Naloxone given 3/5 3/6 6/11
Taken to hospital 4/5 4/6 8/11
Presence at overdose of others <2 weeks of release
Present 17% (19/112) 13% (12/93) 15% (31/205)
Naloxone given 10/19 1/12 11/31
Taken to hospital 12/19 8/12 20/31
Survived 17/19 11/12 28/31
Presence at overdose of others >2 weeks of release
Present 15% (17/112) 15% (13/93) 15% (30/205)
Naloxone given 7/17 2/13 9/30
Taken to hospital 9/17 12/13 21/30
Survived 13/17 11/13 24/30
(Continues)
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expectation of someone else present at 80% of opiate
overdoses (Table 3; Table 1).
Five per cent of RPSQ respondents (10 of 205) had
personally experienced an overdose within the ﬁrst
fortnight—7% (eight of 112) for NOR and 2% (two of 93)
of controls (Fisher’s exact test, P = 0.12). Thereafter, until
re-imprisonment, the proportion personally overdosing
was 5% (11 of 205) for NOR and controls alike.
(c) Witnessed overdoses and actions taken
Fifteen per cent of RPSQ respondents (31 of 205) had
personally witnessed an overdose during the ﬁrst fortnight
post-release—17% (19 of 112) for NOR and 13% (12 of
93) of controls. Thereafter, until re-imprisonment, the
witness proportion was 15% (30 of 205) for NOR and
controls alike.
(d) Opinions about NOR and the N-ALIVE trial
Taking part in N-ALIVE was associated positively with
safer heroin use by 60 of 112 (54%) RPSQ respondents
randomized to NOR and 30 of 93 (32%) of controls
(χ2 on 1 d.f. = 9.37, P< 0.002). Suggestions made by 113
RPSQ respondents were most commonly: ‘everyone should
get naloxone’ (22); ‘everyone should get naloxone not just
50 :50’ (10); ‘availabilityandaccess’ (11); ‘safer perception’
(8); ‘education and awareness’ (8); and ‘research trial a
good idea’ (6); see Supporting information. Fifty difﬁculties
were cited, the top three being: ‘didn’t get naloxone’ (12),
‘no pack on release’ (7) and ‘police not aware’ (6).
Four difﬁculties were potential adverse events: (1)
because police were unaware of the N-ALIVE pilot trial,
one ex-prisoner would have been arrested but for interces-
sion by a drug intervention programme worker; (2)
ex-prisoner’s partner was worried about children ﬁnding
his naloxone; (3) acquaintance of another ex-prisoner took
the naloxone ‘to see if he got a buzz from it’; and (4)
ex-prisoner was unsure how much of naloxone to
administer to a person who had overdosed.
Risk score
Table 4 shows that RPSQ respondents’mean risk score was
not signiﬁcantly different between NOR (3.9) and controls
(3.5). We observed an interaction (P = 0.049) between
randomized assignment, self-reported safer behaviour and
mean risk score: for controls, but not for NOR, RPSQ
respondents’ mean risk score was signiﬁcantly lower for
Table 3. (Continued)
Self-questionnaire NOR Control Total
Naloxone acquisition-rate χ2 on
1 d.f. = 1.46 P = 0.226
4% (5/112) 9% (8/93) 6% (13/205)
Do you think taking part in N-ALIVE changed your own use of heroin in the ﬁrst 2 weeks after release?
No 38% (43/112) 65% (60/93) 50% (103/205)
Safer heroin use 54% (60/112) 32% (30/93) 44% (90/205)
Riskier heroin use 2% (2/112) 3% (3/93) 2% (5/205)
*Fisher’s exact test: P = 0.116. NOR = naloxone-on-release; SD =standard deviation; NA = not applicable; N-ALIVE = NALoxone InVEstigation.
Table 4 Risk score comparison, based on answers to returned prisoner self-questionnaire.
Risk score comparison (lower score, less risky) n Median Mean SD SE (difference) Observed difference (95 % CI for difference)
Random assignment
NOR 112 4.00 3.86 3.34 0.48 0.34
Control 93 2.00 3.52 3.43 (0.59 to 1.27)
Safer behaviour as N-ALIVE participant?
No change/unsafe 115 3.00 3.87 3.54 0.47 0.38
Safer 90 4.00 3.49 3.18 (0.54 to 1.30)
Safer behaviour as N-ALIVE participant? (answers by those assigned to control group)
No change/unsafe 63 3.00 4.03 3.50 0.71 1.60*
Safer 30 2.00 2.43 3.07 (0.20 to 3.00)
Safer behaviour as N-ALIVE participant? (answers by those assigned to NOR group)
No change/unsafe 52 3.50 3.67 3.61 0.64 –0.35*
Safer 60 4.00 4.02 3.12 (1.61 to 0.91)
Test for interaction: difference in differences* [control– naloxone-on-release (NOR)] = 1.94. Standard error (SE) for difference in differences* (control-NOR)
= 0.98. Hence, 95% conﬁdence interval (CI) for difference in differences* is from 0.008 to 3.876 (P = 0.049). SD= standard deviation; N-ALIVE = NALoxone
InVEstigation.
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those who self-reported safer behaviour (2.4) versus not
(4.0).
Drug-related deaths
Only half the DRDs registered in England and Wales in a
speciﬁc calendar year actually occur during that calendar
year [20,21] and so it was necessary to wait at least a year
to report on DRDs.
Nine deaths had occurred in the 12 weeks post-release
among 1557 randomized participants and were registered
with the Ofﬁce for National Statistics before 21 April 2016
(Table 1 and Supporting information). Five were DRDs,
consistent with our null expectation of 9.7 DRDs in 12
weeks after release; but only two DRDs occurred in the
ﬁrst 4 weeks, well below our null expectation of 7.9
(Table 1).
Of the four opioid-related DRDs, three were randomized
to NOR, one of whom was released without his pack. The
participant whose DRD was not opioid-related was also
randomized to NOR and had been released without his
pack.
DISCUSSION
The N-ALIVE pilot trial has randomized more prisoners
than any other prison-based, individually randomized
controlled trial in Europe. We have shown that large-
scale trials of public health interventions are feasible
within prisons. Prisoners themselves showed enthusi-
asm for the N-ALIVE trial—their consent rate was ex-
cellent (72%).
The N-ALIVE pilot trial stopped early because its
own data, together with those from Scotland’s Na-
tional Naloxone Programme, were persuasive that ap-
proximately two-thirds of NOR administrations were
not to the ex-prisoner for whom NOR was assigned.
We had no means of knowing the identities of these
other people: confounding of N-ALIVE’s control group
could have occurred. The N-ALIVE pilot trial ceased
because individualized randomization to NOR cannot
offer a clear-cut answer: other trial designs are
required.
We were concerned that a 50% consent rate combined
with a 50% contact rate for the half randomized to actual
telephone contact would mean that only 195 telephone
interviews would be likely to be achieved from 1557
randomized participants. In practice, the achievement
was lower still, with 81 successful telephone interviews.
By contrast, RPSQs which were designed speciﬁcally to
protect the respondent’s conﬁdentiality achieved their
anticipated response rate.
Other prior assumptions were vindicated by the
feasibility trial. Few actual or potential adverse events were
reported: one reply card informed us that naloxone had
been administered to an overdose victim who had survived
but had experienced withdrawal symptoms; one
ex-prisoner had faced arrest because the police were not
sufﬁciently aware of the N-ALIVE trial; and two
respondents cited their or a partner’s concern for safer
packaging lest children might access the naloxone.
Notwithstanding RPSQ respondents’ eight reports of
overdose during the ﬁrst fortnight for NOR versus two for
controls, and comparable injection rates during the ﬁrst
fortnight post-release (Table 3), RPSQ respondents ran-
domized to NOR self-reported safer heroin use compared
with controls. However, our risk score comparisons
(Table 4) showed a signiﬁcant interaction whereby only
for controls did the mean risk score align with self-reported
safer behaviour. Returned prisoners randomized to NOR
perceived greater safety than their RPSQ answers
demonstrated, which suggests some risk compensation
about which Strang et al. [22] forewarned; see also other
prevention policies, from seat-belt legislation to safety
helmets [23–25], where a degree of risk compensation
detracted in a small way from the policy’s overall beneﬁt.
N-ALIVE participants’ main suggestion was that naloxone
should be made available more widely to all those at risk.
To our knowledge, no previous contemporaneous
before/after policy evaluation and randomized trial of
effectiveness has had the same primary outcome: here,
DRDs or opioid-related DRDs with a 4-week antecedent
of prison release [6,9,14]. The N-ALIVE team convened
its TS-DMC ahead of the release of the third-year results
from Scotland’s National Naloxone Programme [6,19].
Consistency between RPSQ responses on the administra-
tion of NOR (another versus self, 15 : 5) and Scotland’s
data on the utilization of NOR by those who applied for
re-supply (21 : 12) convinced the TS-DMC that an
individually randomized main trial was infeasible because
only one-third of NOR administrations was to the
ex-prisoner and two-thirds to another person whose
identity was unknown to the N-ALIVE trial.
No reliable inference about NOR’s effectiveness for
reducing DRDs in the 12 weeks post-release can be drawn
from the early-cessation N-ALIVE pilot trial: ﬁve registered
DRDs (four randomized to NOR, two of whom were
released without their pack) were fewer than our a priori
null expectation (9.7), perhaps because the expectation
was too high rather than as a reﬂection of NOR’s effective-
ness. However, the 15% fatality rate (95% CI = 6–24%) at
overdoses which our RPSQ respondents witnessed,
typically within 12 weeks of their N-ALIVE release date,
suggests that our ex-prisoners were present at higher-
fatality risk overdoses than suggested by an evidence
synthesis, which gave a 6% fatality rate (95% CI = 2–11%)
at witnessed opioid overdoses [6]. Explanations for the
higher fatality rate reported by our recidivists range from
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chance through assortative mixing of ex-prisoners—who
then share the same high DRD rate post-release—to
ex-prisoners’ high DRD risk being due to a higher fatality
rate per overdose (rather than to higher overdose rate with
common fatality rate per overdose).
The Scottish results [14,15], data on the cost-
effectiveness of naloxone [14,26] WHO recommendations
on naloxone [8], the United Kingdom’s legal change on
provision of naloxone [27], England’s increase in opioid-
related DRDs [28] and prisoners’ support for initiatives
such as the N-ALIVE pilot trial make it timely for England
and others to introduce a funded national naloxone policy;
but also to evaluate, as did Scotland. In summer 2016, the
National Institute for Health Research issued an evaluation
call for naloxone studies in England. This call could address
alternative, licensed non-injectable formulations of
naloxone or divert attention from England’s failure to fund
a naloxone policy: NOR with, or without, take-home
naloxone.
Our ﬁndings add trial-based evidence to the growing
consensus [15,27] that pre-provision of take-home
emergency naloxone can enable life-saving interim
measures to prevent overdose deaths, and that the period
after prison release is not only a time of great concentration
of such deaths but also of opportunity to prevent this major
contribution to the global burden of disease [29].
Research in context
Evidence before this study
The N-ALIVE pilot trial was the ﬁrst randomized controlled
trial to investigate provision of naloxone-on-release (NOR)
to prisoners who have previously injected heroin. The
MRC funded the N-ALIVE pilot trial to investigate the
feasibility of a fully powered randomized trial.
Added value of this study
The N-ALIVE pilot trial has shown that it is feasible to
conduct a large prison-based randomized controlled trial,
with good participation from both prisons and prisoners.
The ﬁnding that two-thirds of administrations of NORwere
to someone unknown to the N-ALIVE pilot trial means that
alternative research designs should be considered for
preventative interventions against fatal overdose.
Implications of all the available evidence
The N-ALIVE pilot trial has demonstrated the feasibility of
recruiting many prisons, and consenting large numbers
of prisoners, to take part in randomized evaluations that
matter to prisoners. The practicality of NOR has now been
demonstrated in two prison systems (by Scotland’s
National Naloxone Policy and by the N-ALIVE pilot trial)
and so prisons, internationally, can deliver NOR.
Scotland’s non-randomized before/after policy
evaluation demonstrated the effectiveness of NOR and
community-based take-home naloxone (jointly) for
reducing opioid-related deaths during the 4 weeks after
prison release. Two-thirds of administrations of NOR
(Scotland; N-ALIVE) were to someone other than the
ex-prisoner for whom NOR was prescribed. The N-ALIVE
pilot trial reacted promptly to external data from Scotland
and from the trial itself to close the N-ALIVE trial to
recruitment.
Between 6000 and 8000 drug-induced deaths are
reported in Europe every year, with opioids their major
cause. The European Monitoring Centre for Drugs and
Drug Addiction exhorts Member States that many of these
deaths could be prevented by adequate peer intervention
using naloxone. Age-related rising numbers of opioid-
related DRDs complicate before-and-after evaluations, as
in Scotland.
Clinical Trial Registration
N-ALIVE pilot TRIAL: ISRCTN34044390.
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